| Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: phase 3 study O Sabri, MN Sabbagh, J Seibyl, H Barthel, H Akatsu, Y Ouchi, K Senda, ... Alzheimer's & dementia 11 (8), 964-974, 2015 | 526 | 2015 |
| Tumor targeting by an aptamer BJ Hicke, AW Stephens, T Gould, YF Chang, CK Lynott, J Heil, ... Journal of Nuclear Medicine 47 (4), 668-678, 2006 | 511 | 2006 |
| Application of locked nucleic acids to improve aptamer in vivo stability and targeting function KS Schmidt, S Borkowski, J Kurreck, AW Stephens, R Bald, M Hecht, ... Nucleic acids research 32 (19), 5757-5765, 2004 | 374 | 2004 |
| Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study M Fassnacht, A Berruti, E Baudin, MJ Demeure, J Gilbert, H Haak, ... The lancet oncology 16 (4), 426-435, 2015 | 363 | 2015 |
| Escort aptamers: a delivery service for diagnosis and therapy BJ Hicke, AW Stephens The Journal of clinical investigation 106 (8), 923-928, 2000 | 295 | 2000 |
| Assessment of 18F-PI-2620 as a biomarker in progressive supranuclear palsy M Brendel, H Barthel, T van Eimeren, K Marek, L Beyer, M Song, C Palleis, ... JAMA neurology 77 (11), 1408-1419, 2020 | 190 | 2020 |
| High-affinity RNA ligands to human α-thrombin MF Kubik, AW Stephens, D Schneider, RA Marlar, D Tasset Nucleic acids research 22 (13), 2619-2626, 1994 | 185 | 1994 |
| Bioconjugation of macromolecules W Pieken, K Hill, B Eaton, D McGee, K Vagle, L Gold, A Stephens US Patent 6,737,236, 2004 | 178 | 2004 |
| Discovery and preclinical characterization of [18F]PI-2620, a next-generation tau PET tracer for the assessment of tau pathology in Alzheimer’s disease and other … H Kroth, F Oden, J Molette, H Schieferstein, F Capotosti, A Mueller, ... European journal of nuclear medicine and molecular imaging 46, 2178-2189, 2019 | 172 | 2019 |
| Evaluation of critical groups required for the binding of heparin to antithrombin. DH Atha, AW Stephens, RD Rosenberg Proceedings of the National Academy of Sciences 81 (4), 1030-1034, 1984 | 166 | 1984 |
| Tau PET imaging with 18F-PI-2620 in patients with Alzheimer disease and healthy controls: a first-in-humans study A Mueller, S Bullich, O Barret, J Madonia, M Berndt, C Papin, A Perrotin, ... Journal of Nuclear Medicine 61 (6), 911-919, 2020 | 147 | 2020 |
| Association of amyloid positron emission tomography with changes in diagnosis and patient treatment in an unselected memory clinic cohort: the ABIDE project A de Wilde, WM van der Flier, W Pelkmans, F Bouwman, J Verwer, ... JAMA neurology 75 (9), 1062-1070, 2018 | 142 | 2018 |
| Specific PET Imaging of xC− Transporter Activity Using a 18F-Labeled Glutamate Derivative Reveals a Dominant Pathway in Tumor Metabolism N Koglin, A Mueller, M Berndt, H Schmitt-Willich, L Toschi, AW Stephens, ... Clinical Cancer Research 17 (18), 6000-6011, 2011 | 133 | 2011 |
| Sequence variation in heparin octasaccharides with high affinity for antithrombin III DH Atha, AW Stephens, A Rimon, RD Rosenberg Biochemistry 23 (24), 5801-5812, 1984 | 116 | 1984 |
| 18F-Florbetaben PET beta-amyloid binding expressed in Centiloids CC Rowe, V Doré, G Jones, D Baxendale, RS Mulligan, S Bullich, ... European journal of nuclear medicine and molecular imaging 44, 2053-2059, 2017 | 114 | 2017 |
| Systematic evolution of ligands by exponential enrichment: tissue selex KB Jensen, H Chen, KN Morris, A Stephens, L Gold US Patent 5,712,375, 1998 | 113 | 1998 |
| Systematic evolution of ligands by exponential enrichment: tissue selex KB Jensen, H Chen, KN Morris, A Stephens, L Gold US Patent 5,789,157, 1998 | 112 | 1998 |
| Phase I study of intermittent oral dosing of the insulin-like growth factor-1 and insulin receptors inhibitor OSI-906 in patients with advanced solid tumors RL Jones, ES Kim, P Nava-Parada, S Alam, FM Johnson, AW Stephens, ... Clinical cancer research 21 (4), 693-700, 2015 | 106 | 2015 |
| Nucleic acid ligands of tissue target A Stephens, L Gold, U Speck US Patent 6,127,119, 2000 | 106 | 2000 |
| A phase I study of continuous oral dosing of OSI-906, a dual inhibitor of insulin-like growth factor-1 and insulin receptors, in patients with advanced solid tumors I Puzanov, CR Lindsay, L Goff, J Sosman, J Gilbert, J Berlin, S Poondru, ... Clinical cancer research 21 (4), 701-711, 2015 | 105 | 2015 |
Ludger DinkelborgLife Molecular ImagingVerified email at life-mi.com
